2022. A randomized, double-blind, placebo-controlled, Phase 1/2a trial protocol to assess the safety and efficacy of TAK-101 administered by microneedles in patients with celiac disease. Principles and Practice of Clinical Research. 8, 3 (Dec. 2022), 37–48. DOI:https://doi.org/10.21801/ppcrj.2022.83.5.